
Imecta6 mg
Beacon Pharmaceuticals PLC
Ivermectin is an antiparasitic (anthelmintic) medicine.
Ivermectin is an antiparasitic (anthelmintic) medicine. Its evidence-supported uses are classified below by strength of evidence.
Ivermectin should be used strictly for these established and guideline-supported parasitic and dermatological indications. It should not be used for the prevention or treatment of viral illnesses, as this is not an approved or evidence-supported use.
Ivermectin tablets should be taken orally with a full glass of water, on an empty stomach (at least 1 hour before a meal), as food increases systemic absorption. Doses are calculated based on body weight.
| Indication | Adult dose | Notes |
|---|---|---|
| Strongyloidiasis | Single oral dose of approximately 200 mcg/kg body weight | Follow-up stool examinations are recommended to confirm parasitological cure; a repeat course may be needed if follow-up examination shows persistent infection. |
| Onchocerciasis | Single oral dose of approximately 150 mcg/kg body weight | Retreatment is generally recommended, commonly at intervals of about 12 months (as short as 3 months has been used in specific programme settings), because Ivermectin does not kill the adult worm. |
| Scabies | Single oral dose of approximately 200 mcg/kg, often repeated after 8-14 days | Usually combined with topical scabicide; two-dose regimen improves cure rate. Crusted scabies may need additional doses per specialist guidance. |
| Lymphatic filariasis (mass drug administration) | Weight/age-based single dose, given in combination with albendazole (and/or diethylcarbamazine per national programme) | Ivermectin is used as combination therapy for this indication, not as monotherapy. |
See Use in Special Populations for pediatric, renal and hepatic considerations, and Contraindications/Precautions for the Loa loa caution relevant to onchocerciasis treatment.
Most patients tolerate Ivermectin well. Reported adverse effects vary somewhat by indication because some reactions reflect the host response to dying parasites (Mazzotti-type reaction) rather than direct drug toxicity.
Patients should seek medical attention promptly for severe rash, breathing difficulty, yellowing of skin/eyes, or altered mental status.
Ivermectin is contraindicated in patients with a known hypersensitivity to Ivermectin or to any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.